Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Plans to Cut 450 Jobs via Voluntary Redundancy Program
June 4, 2021
- Keio Upstart, Novo Nordisk Ink Global Deal on iPSC-Based Heart Therapy
June 2, 2021
- Amgen Gets Rights to Kyowa Kirin’s Atopic Dermatitis Drug
June 2, 2021
- Incyte’s Debuts Its 1st Product in Japan; Mitsubishi’s Uplizna Now Available Too
June 2, 2021
- FDA Target Date for Vadadustat Set for March 29: Otsuka/Akebia
June 2, 2021
- Shionogi, Chiyoda Eye JV for Continuous Manufacturing of APIs, Intermediates
June 2, 2021
- SGLT2 Inhibitors Again Poised for Double-Digit Growth in FY2021; Forxiga Overtakes Jardiance in April
June 1, 2021
- 52 More Nichi-Iko Products Face Supply Stoppage as Risk Assessment Continues
June 1, 2021
- Jail Terms Sought for 2 Ono Employees over Onoact-Tied Bribery Charges
June 1, 2021
- Chugai Becomes 1st Japan Drug Maker to Introduce Cryo-EM
June 1, 2021
- AstraZeneca Seeks Japan Approval for Tezepelumab in Severe Asthma
June 1, 2021
- Nipro Rolls Out Seven-Dose Syringe for Pfizer COVID-19 Vaccine
June 1, 2021
- Sanofi Introduces 1st NovoRapid Biosimilar in Japan
June 1, 2021
- Ayumi Curbs Enbrel Biosimilar Shipments in Fallout from Indian API Supply Disruption
June 1, 2021
- Pfizer Vaccine Now OK’ed for Adolescents, 1-Month Storage in Refrigerators
June 1, 2021
- Kobayashi Kako Submits Biz Improvement Plan Over Fudged Drug Filings
May 31, 2021
- EA Pharma/Kissei Seek Japan Approval of Ulcerative Colitis Drug
May 31, 2021
- AZ to Take Over Japan Synagis Rights from AbbVie in July as Global Pact Expires
May 31, 2021
- Yoshindo/Teijin Halt Enbrel Shipments as COVID-19 Stalls Indian API Supplies
May 31, 2021
- mRNA CDMO Arcalis Aims for One Stop Provider for Seed Verification, R&D, Commercial Production
May 31, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…